{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:13:23Z","timestamp":1789881203935,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013119","name":"PharmaMar","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013119","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.esmoop.2024.103995","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T14:08:42Z","timestamp":1732716522000},"page":"103995","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pazopanib in the real-world setting in soft tissue sarcomas: data from the Italian national registry"],"prefix":"10.1016","volume":"9","author":[{"given":"B.","family":"Vincenzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7934-9034","authenticated-orcid":false,"given":"P.P.","family":"Olimpieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7784-4506","authenticated-orcid":false,"given":"S.","family":"Celant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0219-119X","authenticated-orcid":false,"given":"A.","family":"Mazzocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cortellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Comandone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3725-5106","authenticated-orcid":false,"given":"L.","family":"Tomassini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Di Segni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.G.","family":"Casali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2024.103995_bib1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2045-3329-2-14","article-title":"The epidemiology of sarcoma","volume":"2","author":"Burningham","year":"2012","journal-title":"Clin Sarcoma Res"},{"key":"10.1016\/j.esmoop.2024.103995_bib2","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJMra041866","article-title":"Soft-tissue sarcomas in adults","volume":"353","author":"Clark","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2024.103995_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/PAT.0000000000000050","article-title":"WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition","volume":"46","author":"Jo","year":"2014","journal-title":"Pathology"},{"key":"10.1016\/j.esmoop.2024.103995_bib4","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2002.07.154","article-title":"Primary adult soft tissue sarcoma: time-dependent influence of prognostic variables","volume":"20","author":"Stojadinovic","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103995_bib5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.103995_bib6","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1002\/cncr.32795","volume":"126","author":"D\u2019Ambrosio","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2024.103995_bib7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1186\/1471-2407-13-385","article-title":"Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review","volume":"13","author":"Sharma","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2024.103995_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/14737140.2020.1753511","article-title":"The current reality of soft tissue sarcomas: advances, controversies, areas for improvement, and promising new treatments","volume":"20","author":"Blay","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.esmoop.2024.103995_bib9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/1078-0432.CCR-10-1603","article-title":"Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis","volume":"17","author":"Gril","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2024.103995_bib10","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","article-title":"Phase I trial of pazopanib in patients with advanced cancer","volume":"15","author":"Hurwitz","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2024.103995_bib11","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2024.103995_bib12","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","volume":"27","author":"Sleijfer","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103995_bib13","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1002\/cncr.30926","article-title":"Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma","volume":"123","author":"Samuels","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2024.103995_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2045-3329-4-7","article-title":"Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience","volume":"4","author":"Frezza","year":"2014","journal-title":"Clin Sarcoma Res"},{"key":"10.1016\/j.esmoop.2024.103995_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13569-015-0022-2","article-title":"Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience","volume":"5","author":"Maruzzo","year":"2015","journal-title":"Clin Sarcoma Res"},{"key":"10.1016\/j.esmoop.2024.103995_bib16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ygyno.2016.03.024","article-title":"Outcome of uterine sarcoma patients treated with pazopanib: a retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072","volume":"142","author":"Benson","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.esmoop.2024.103995_bib17","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(18)30676-4","article-title":"Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial","volume":"20","author":"Martin-Broto","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.103995_bib18","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/cncr.29961","article-title":"The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: a Japanese Musculoskeletal Oncology Group (JMOG) study","volume":"122","author":"Nakamura","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2024.103995_bib19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/0284186X.2016.1234068","article-title":"Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis","volume":"56","author":"Koll\u00e1r","year":"2017","journal-title":"Acta Oncol"},{"key":"10.1016\/j.esmoop.2024.103995_bib20","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1080\/0284186X.2017.1332779","article-title":"Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study","volume":"56","author":"Gelderblom","year":"2017","journal-title":"Acta Oncol"},{"key":"10.1016\/j.esmoop.2024.103995_bib21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12032-017-1030-2","article-title":"Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma","volume":"34","author":"Jones","year":"2017","journal-title":"Med Oncol"},{"key":"10.1016\/j.esmoop.2024.103995_bib22","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1634\/theoncologist.2017-0408","article-title":"Clinical activity of pazopanib in patients with advanced desmoplastic small round cell tumor","volume":"23","author":"Menegaz","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2024.103995_bib23","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1634\/theoncologist.2017-0161","article-title":"Activity of pazopanib and trabectedin in advanced alveolar soft part sarcoma","volume":"23","author":"Stacchiotti","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2024.103995_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0219","article-title":"Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma a multi-institutional case series","volume":"4","author":"Frezza","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2024.103995_bib25","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/ijc.34309","article-title":"Trabectedin use in soft-tissue sarcoma patients in a real-world setting: data from an Italian national drug-access registry","volume":"152","author":"Vincenzi","year":"2023","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmoop.2024.103995_bib26","article-title":"Shedding new light on COVID-19 therapeutics during the omicron era: a deeper dive into real-world data","volume":"31","author":"De Vito","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.esmoop.2024.103995_bib27","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/biostatistics\/kxac009","article-title":"A\u00a0flexible parametric accelerated failure time model and the extension to time-dependent acceleration factors","volume":"24","author":"Crowther","year":"2023","journal-title":"Biostatistics"},{"key":"10.1016\/j.esmoop.2024.103995_bib28","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/modpathol.2017.54","article-title":"Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model","volume":"30","author":"Demicco","year":"2017","journal-title":"Mod Pathol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924017654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924017654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T04:43:48Z","timestamp":1736311428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924017654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2059702924017654"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103995","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pazopanib in the real-world setting in soft tissue sarcomas: data from the Italian national registry","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103995","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103995"}}